Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean-Pierre J Issa

Showing results (191-200 of 204) with videos related to

Pageof 21
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2008
Epigenetic-genetic interactions in the APC/WNT, RAS/RAF, and P53 pathways in colorectal carcinomaYutaka Suehiro, Chi Wai Wong, Lucian R Chirieac, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2002
Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up resultsHagop M Kantarjian, Moshe Talpaz, Susan O'Brien, et al.
The Lancet. Oncology|August 29, 2017
Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trialHagop M Kantarjian, Gail J Roboz, Patricia L Kropf, et al.
Genome Biology|November 27, 2019
DNA methylation aging clocks: challenges and recommendationsChristopher G Bell, Robert Lowe, Peter D Adams, et al.
Science Translational Medicine|March 28, 2014
Epigenetic reprogramming of HOXC10 in endocrine-resistant breast cancerThushangi N Pathiraja, Shweta R Nayak, Yuanxin Xi, et al.
Blood Advances|June 5, 2023
Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized studyPierre Fenaux, Marco Gobbi, Patricia L Kropf, et al.
Blood|May 4, 2022
Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapyAmer M Zeidan, Pierre Fenaux, Marco Gobbi, et al.
Biorxiv : the Preprint Server for Biology|November 28, 2024
Bone marrow microenvironment signatures associate with patient survival after guadecitabine and atezolizumab therapy in HMA-resistant MDSH Josh Jang, Guillermo Urrutia, Andreas Due Orskov, et al.
Cancer Discovery|April 27, 2013
Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic driversCurtis R Pickering, Jiexin Zhang, Suk Young Yoo, et al.
Blood Neoplasia|June 17, 2026
Bone marrow immunosuppressive states associate with survival after guadecitabine and atezolizumab therapy in HMA-R/R MDSH Josh Jang, Guillermo Urrutia, Andreas Due Ørskov, et al.
Pageof 21

Showing results (191-200 of 204) with videos related to

Sort By:
Pageof 21
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2008
Epigenetic-genetic interactions in the APC/WNT, RAS/RAF, and P53 pathways in colorectal carcinomaYutaka Suehiro, Chi Wai Wong, Lucian R Chirieac, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2002
Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up resultsHagop M Kantarjian, Moshe Talpaz, Susan O'Brien, et al.
The Lancet. Oncology|August 29, 2017
Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trialHagop M Kantarjian, Gail J Roboz, Patricia L Kropf, et al.
Genome Biology|November 27, 2019
DNA methylation aging clocks: challenges and recommendationsChristopher G Bell, Robert Lowe, Peter D Adams, et al.
Science Translational Medicine|March 28, 2014
Epigenetic reprogramming of HOXC10 in endocrine-resistant breast cancerThushangi N Pathiraja, Shweta R Nayak, Yuanxin Xi, et al.
Blood Advances|June 5, 2023
Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized studyPierre Fenaux, Marco Gobbi, Patricia L Kropf, et al.
Blood|May 4, 2022
Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapyAmer M Zeidan, Pierre Fenaux, Marco Gobbi, et al.
Biorxiv : the Preprint Server for Biology|November 28, 2024
Bone marrow microenvironment signatures associate with patient survival after guadecitabine and atezolizumab therapy in HMA-resistant MDSH Josh Jang, Guillermo Urrutia, Andreas Due Orskov, et al.
Cancer Discovery|April 27, 2013
Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic driversCurtis R Pickering, Jiexin Zhang, Suk Young Yoo, et al.
Blood Neoplasia|June 17, 2026
Bone marrow immunosuppressive states associate with survival after guadecitabine and atezolizumab therapy in HMA-R/R MDSH Josh Jang, Guillermo Urrutia, Andreas Due Ørskov, et al.
Pageof 21